Ascendis Pharma ASASND
Mentioned
Impact on stocks 1
Health Care
Ascendis Pharma ASAscendis Pharma reported second quarter 2026 total revenue of €339 million, up from €158 million a year earlier, driven by strong demand for its TransCon products. Product revenue reached €315 million, a 105% year-over-year increase, comprising €252 million for YORVIPATH, €55 million for SKYTROFA, and €8 million for YUVIWEL. The company posted an operating profit of €220 million, including a €158 million gain from the sale of a Rare Pediatric Disease Priority Review Voucher, and a net profit of €207 million, or €2.83 per diluted share. Ascendis also completed the conversion of all outstanding $575 million of 2.25% Convertible Senior Notes due 2028 and was added to multiple Russell U.S. Indexes. Cash and cash equivalents totaled €812 million as of June 30, 2026.
Ascendis Pharma AS